Boston – September 15, 2026 -- EMD Serono, Inc., the healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and Canada, has acquired two preclinical fertility drug programs from PostEra, a biotech firm built on artificial intelligence-driven small molecule discovery.

Boston – September 15, 2026 -- EMD Serono, Inc., the U.S. and Canada healthcare business of Merck KGaA, Darmstadt, Germany, has acquired two preclinical fertility drug programs from Boston-based biotech PostEra, the companies announced.

Boston – September 15, 2026 -- EMD Serono, Inc., the U.S. and Canada healthcare business of Merck KGaA, Darmstadt, Germany, has acquired two preclinical fertility drug programs from PostEra, a biotechnology company that uses artificial intelligence for small-molecule drug discovery.